Pfizer's High- Yield, Sustainability Concerns

This is a news story, published by Yahoo Finance, that relates primarily to Pfizer news.

Pfizer news

For more Pfizer news, you can click here:

more Pfizer news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

high dividend yield

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Pharmaceutical giant Pfizer news, yield dividend stocks news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

high dividend

The Motley Fool

•

Is Pfizer's 5.7% Dividend Yield Worth the Risk?

Summary

Nutrition label

83% Informative

Pfizer 's 5.7% dividend yield is one of the highest in the entire healthcare sector.

The company's payout ratio of 436% raises significant concerns about sustainability.

Pfizer has implemented a cost-saving plan targeting $4 billion in net savings by year-end .

Management's steadfast commitment to dividend growth, cost-cutting measures, and a promising drug pipeline suggest the potential for a turnaround.

While the elevated ratio is a concern, the company's strong position and proven innovation offer some safety for investors.

The Motley Fool Stock Advisor analyst team identified what they believe are the 10 best stocks for investors to buy now and Pfizer wasn’t one of them.

The 10 stocks that made the cut could produce monster returns in the coming years .

Consider when Nvidia made this list on April 15, 2005 ... if you invested $ 1,000 at the time of our recommendation, you’d have $ 729,857 !.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive